Nicotine therapeutic benefits: Difference between revisions

Line 370:

**Citation: van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009 Jan;60(1):114-22. doi: 10.1002/art.24177. PMID: 19116908.

= '''~~Atopic Dermatitis~~''' =

='''Ataxia'''=

~~=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37454697/ Association of Atopic Dermatitis with Substance Use Disorders: A Case-Control Study in the All of Us Research Program.] ===~~

* Joshi TP, Bancroft A, DeLeon D, Garcia D, Kunisetty B, Truong P, Kim SJ. J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01361-0. doi: 10.1016/j.jaad.2023.06.051. Online ahead of print. PMID: 37454697 No abstract available.

* Patients with AD, compared to controls, were more likely to use cannabis (4.4% vs 2.7%, 60 P <0.01), hallucinogens (3.2% vs 1.8%, P <0.01), opioids (3.5% vs 1.3%, P <0.01), and 61 stimulants (2.3% vs 1.5%, P <0.01) and less likely to use e-cigarettes (10.8% vs 15.6%, P <0.01) 62 and regular cigarettes (39.0% vs 56.0%, P <0.01).

* In multivariable analysis adjusted for age, 63 income, insurance type, race, sex, depression, and anxiety, only the associations with cannabis 64 (aOR 1.49, 95% CI 1.24-1.80), e-cigarette (aOR 0.71, 95% CI 0.65-0.77), and regular cigarette 65 use (aOR 0.65, 95% CI 0.63-0.68) persisted (Table I)

= '''Auditory''' =

@@ Line 370: / Line 370: @@
 **Citation: van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009 Jan;60(1):114-22. doi: 10.1002/art.24177. PMID: 19116908.
-= '''Atopic Dermatitis''' =
+='''Ataxia'''=
-=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37454697/ Association of Atopic Dermatitis with Substance Use Disorders: A Case-Control Study in the All of Us Research Program.] ===
-* Joshi TP, Bancroft A, DeLeon D, Garcia D, Kunisetty B, Truong P, Kim SJ. J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01361-0. doi: 10.1016/j.jaad.2023.06.051. Online ahead of print. PMID: 37454697 No abstract available.
-* Patients with AD, compared to controls, were more likely to use cannabis (4.4% vs 2.7%, 60 P <0.01), hallucinogens (3.2% vs 1.8%, P <0.01), opioids (3.5% vs 1.3%, P <0.01), and 61 stimulants (2.3% vs 1.5%, P <0.01) and less likely to use e-cigarettes (10.8% vs 15.6%, P <0.01) 62 and regular cigarettes (39.0% vs 56.0%, P <0.01).
-* In multivariable analysis adjusted for age, 63 income, insurance type, race, sex, depression, and anxiety, only the associations with cannabis 64 (aOR 1.49, 95% CI 1.24-1.80), e-cigarette (aOR 0.71, 95% CI 0.65-0.77), and regular cigarette 65 use (aOR 0.65, 95% CI 0.63-0.68) persisted (Table I)
 = '''Auditory''' =